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PENENTUAN SUBSET LIMFOSIT PADA PESAKIT “MAJOR 




 “Major Depressive Disorder” telah dikaitkan dengan gangguan sistem imun. 
Walaupun banyak kajian mengenai pengaktifan tindak balas imun semula jadi pada 
masa ini menguasai cabang penyelidikan, namun gangguan dalam sistem imun 
adaptif terutamanya dalam peredaran subset limfosit jarang diterokai. Beberapa 
kajian menunjukkan bahawa tahap keterukan penyakit MDD adalah penting dalam 
mengesan sejauh mana perubahan imun pada pesakit MDD. Objektif kajian ini 
adalah untuk menentukan faktor penyumbang kepada penyakit MDD, symptom biasa 
pesakit MDD berdasarkan “Beck Depression Inventory (BDI)” dan “Montgomery-
Asberg Depression Rating Scale (MADRS)”, peratusan serta bilangan mutlak subset 
limfosit dalam pesakit MDD dan perbandingannya antara tahap keterukan penyakit 
ini. Kajian ini melibatkan 47 pesakit MDD yang diambil dari Kinik Psikatri, Hospital 
Universiti Sains Malaysia (HUSM) dan 47 individu sihat. Pesakit MDD didiagnosa 
mengikut kriteria “Diagnostic and Statistical Manual of Mental Disorders Fifth 
Edition (DSM-V)”. Simptom-simptom dan tahap keterukan penyakit MDD dinilai 


















 NK sel dan CD19
+ 
B sel ditentukan dengan menggunakan teknik 
“immunophenotyping”. “Mann-Whitney” digunakan untuk membandingkan 
peratusan dan bilangan mutlak subset limfosit antara pesakit MDD dan individu 





mutlak subset limfosit antara pesakit MDD dengan tahap keterukan yang berbeza. 
Hasil kajian menunjukkan bahawa mereka yang berkahwin, perokok, mempunyai 
tahap pendidikan yang rendah dan tinggal di kawasan luar bandar mempunyai risiko 
yang lebih tinggi untuk mendapat penyakit MDD. Berdasarkan BDI, simptom yang 
biasa dilaporkan oleh pesakit MDD adalah keletihan dan cepat marah. Walau 
bagaimanapun berdasarkan MADRS, pesakit MDD juga mempunyai ketegangan 
dalaman, masalah tumpuan, ketidakupayaan untuk merasa dan pemikiran pesimis. 
Kajian ini menunjukkan bahawa tiada perbezaan yang signifikan dalam peratusan 
dan bilangan mutlak sel CD4
+ 
T (p=0.148; p=0.190), sel CD8
+





 NK (p=0.731; p=0.530), dan sel CD19
+
 B (p=0.136; p=0.148) 
antara pesakit MDD dan individu sihat. Walau bagaimanapun, kami mendapati 











 Treg (p=0.003; p=0.001) pada pesakit MDD lebih tinggi berbanding 
dengan individu sihat. Kajian ini juga menunjukkan tiada perbezaan yang signifikan 
dalam peratusan dan bilangan mutlak subset limfosit antara pesakit MDD biasa, 













DETERMINATION OF LYMPHOCYTE SUBSETS IN PATIENTS WITH 
MAJOR DEPRESSIVE DISORDER (MDD) 
ABSTRACT 
 
 Major depressive disorder (MDD) has been associated with dysregulation of 
immune system. While many studies on activation of innate immune response 
currently dominates the research area, the dysregulation in adaptive immune system 
especially in circulating lymphocyte subsets has rarely been explored. Some studies  
indicated that the severity of MDD is important with respect to the extent of the 
immune changes in MDD patients. The objective of this study was to determine the 
predisposing factors of MDD and the common symptoms in MDD patients based on 
Beck Depression Inventory (BDI) and Montgomery-Asberg Depression Rating Scale 
(MADRS), and to determine the percentage and absolute count of lymphocyte 
subsets in MDD patients and their comparison between different severity of the 
disease. This study involved 47 MDD patients recruited from Psychiatric Clinic, 
Hospital Universiti Sains Malaysia (HUSM) and 47 healthy controls. MDD patients 
were diagnosed according to Diagnostic and Statistical Manual of Mental Disorders 
Fifth Edition (DSM-V) criteria. The symptoms and severity of MDD was assessed 






















B cells were determined by using immunophenotyping technique. 
Mann-Whitney test was used to compare the percentage and absolute count of 
lymphocyte subsets between MDD patients and healthy controls. Kruskal-Wallis test 





between different severity of MDD. The results showed that those married, smoker, 
possess lower educational level and living in rural area have higher risk for MDD. 
Based on BDI, the most common symptoms reported by our MDD patients were 
fatigue and irritability. While based on MADRS, MDD patients also have inner 
tension, concentration difficulties, inability to feel and pessimistic thought. This 
study showed that there were no significant differences in the percentage and 
absolute count of CD4
+ 
T cells (p=0.148; p=0.190), CD8
+ 





 NK cells (p=0.731; p=0.530), and CD19
+
 B cells (p=0.136; 
p=0.148) between MDD patients and healthy controls. However, we found a 











 Treg cells (p=0.003; p=0.001) in MDD patients compared 
with healthy controls. This study also showed that there were no significant 
differences in the percentage and absolute count of lymphocyte subsets between 














1.1 Major Depressive Disorder (MDD) 
Major depressive disorder (MDD) is the most common mental disorder 
reported worldwide. MDD is characterised by the presence of psychological 
symptoms like sadness, loss of interest or pleasure, feelings of guilt or worthlessness 
and recurrent thoughts of death or suicide. These symptoms present together with 
somatic symptoms like sleep or appetite disturbance, significant weight loss, 
concentration difficulties, physical agitation or retardation and fatigue (Fava and 
Kendler, 2000). MDD can be long-lasting or recurrent and its condition significantly 
affects an individual's family and personal relationships, work or school life, and 
general health (Moussavi et al., 2007).  
 
1.1.1 Epidemiology of MDD 
Major depressive disorder is a mental disorder that can affect all people 
regardless of age, geographic location, demographics, or social position (Firdaus 
Mukhtar and Tian P.S. Oei, 2011b). According to the World Health Organization 
(WHO), an estimated 350 million people of all ages suffer from depression (World 
Health Organization, 2016). It is projected that MDD will be the second leading 





global burden of disease (World Health Organization, 2016). In 2014, about 6.7% of 
the U.S population aged 18 or older had MDD (National Institute of Mental Health, 
2016b).  
 
Across the Asia Pacific region, the rates of current or 1-month MDD ranged from 1.3 
to 5.5%, while the rates of MDD in the previous year ranged from 1.7 to 6.7% (Chiu, 
2004). The lifetime occurrence of MDD in any country is between 8 to 10% 
(Malaysian Psychiatric Association, 2006). MDD is predicted to affect about 2.3 
million people in Malaysia and at some point in their lives (Firdaus Mukhtar and 
Tian P.S. Oei, 2011b). The prevalence of MDD in general population in Malaysia is 
about 8 to 12% regardless of the geographical differences of the study setting (Ng, 
2014). While in the primary care population, the prevalence ranged from 6.7 to 
14.4% (Firdaus Mukhtar and Tian P. S. Oei, 2011).  
 
Epidemiologic studies consistently shown that women were twice as likely as men to 
be classified as having MDD (Van de Velde et al., 2010; Bromet et al., 2011). In the 
south-east Asian region (SEAR), 7 to 12% of men are at a lifetime risk of MDD, 
while the incidence of MDD among women is 20 to 25% (Khan et al., 2011). The 
mean age of onset for MDD is in the late 20s (Bromet et al., 2011). In Asia Pacific 
region, the rates of MDD are highest in those aged 25 to 44 (Chiu, 2004). MDD is 
more common in urban than in rural population (Wang, 2004) and the prevalence is 
higher in groups with lower socioeconomic status (Lorant et al., 2007; Meriam Omar 






1.1.2 Aetiology of MDD 
Major depressive disorder is a multifactorial and heterogeneous group of 
disorder involving both environmental and biological factors. Childhood trauma and 
stressful life events such as separation, loss of someone, sexual abuse and poverty are 
the most common causes of MDD (Kendler et al., 2002; Shapero et al., 2014). 
Besides that, MDD was also associated with history of chronic illness and social life 
events such as drug abused and alcohol consumption. Previous study showed that 
people with chronic illness was 2.7 times at risk to develop MDD, while those with 
recent alcohol consumption or drug abuse were 39.1 times at risk (Aris et al., 2014). 
The study also reported that among those MDD patients presented with chronic 
illness, majority of them suffered from Hypertension and Diabetes Mellitus (Aris et 
al., 2014). 
 
Genetic factors also play a crucial role in the aetiology of MDD. Evidence from twin 
studies suggested that MDD has a concordance of 40% to 50%, while family studies 
indicated that first-degree relatives of depressed individuals are about three times as 
likely to develop MDD as the general population (Tsuang and Faraone, 1990). It has 
been found that genetic polymorphisms of serotonin transporter gene (5-HTTLPR) 
are involved in the development of MDD. Caspi et al. (2003) reported that 
individuals with one or two copies of the short allele of serotonin transporter gene (5-
HTTLPR) experienced more depressive symptoms and have higher rates of MDD in 
response to stressful life events than individual who is homozygous for the long 






In addition, neuroimaging studies showed that MDD patients had increased volume 
of the lateral ventricles and adrenal gland and smaller volumes of the basal ganglia, 
thalamus, hippocampus, and frontal lobe compared to healthy controls (Koolschijn et 
al., 2009). In conclusion, the onset of MDD involved a combination of genetic, 
psychologic and environmental factors. 
 
1.1.3 Pathophysiology of MDD 
The pathophysiology of MDD has not been clearly defined. However, several 
biological mechanism with a possible role in the pathophysiology of MDD have been 
identified. One of the major theories of MDD pathogenesis is the monoamine 
deficiency theory (Hasler, 2010). This theory suggested that the underlying 
pathophysiological basis of depression is the depletion of the neurotransmitter 
serotonin, norepinephrine or dopamine in the central nervous system (Dunlop and 
Nemeroff, 2007; Hasler, 2010). Most of the serotonergic, noradrenergic and 
dopaminergic neurons are located in midbrain and brainstem nuclei which project to 
large areas of the entire brain. This monoaminergic systems are involved in the 
regulation of a broad range of brain functions, including mood, attention, reward 
processing, sleep, appetite, and cognition (Belmaker and Agam, 2008). The 
deficiency of the neurotransmitters produces a number of physiological and 
behavioural alterations that resemble the symptoms of MDD, including low mood, 
decreased appetite, sleep  disturbance, poor concentration and psychomotor alteration 
(Delgado, 2000). Almost every compound that inhibits monoamine reuptake, leading 
to an increased concentration of monoamines in the synaptic cleft, has been proven 






The hyperactivity of hypothalamic pituitary adrenal (HPA) axis is also involved in 
the pathophysiology of MDD (Vreeburg et al., 2009; Stetler and Miller, 2011). This 
hyperactivity is caused by malfunctioning of glucocorticoid receptors impairing the 
negative feedback circuit of the HPA-axis. Glucocorticoid receptor malfunction 
might also cause MDD via impaired neurogenesis and reduced hippocampus 
volumes (Manji et al., 2003; Pariante and Lightman, 2008). Corticotropin releasing 
hormone (CRH) and vasopressin (AVP) are released from the hypothalamus in 
response to the perception of psychological stress by cortical brain regions. These 
hormones induce the secretion of adrenocorticotrophic hormone (ACTH) from the 
pituitary, which stimulates the adrenal gland to release glucocorticoid (cortisol in 
human) into plasma. Glucocorticoids then interact with their receptors in multiple 
target tissues including the HPA axis, where they are responsible for feedback 
inhibition on both CRH and AVP from the hypothalamus and directly on secretion of 
ACTH from pituitary (Vreeburg et al., 2009). The activated HPA axis not only 
regulates body peripheral functions such as metabolism and immunity but also has 
profound effects on the brain. For example, glucocorticoids regulate neuronal 
survival, neurogenesis, the sizes of complex anatomical structures such as the 
hippocampus, the acquisition of new memories and emotional appraisal of events 
(Vreeburg et al., 2009; Stetler and Miller, 2011). 
 
Mounting data indicate that cytokine plays a major role in neuropsychiatric diseases, 
including MDD (Schiepers et al., 2005; Miller et al., 2009). Patients with MDD have 
been shown to exhibit increases in inflammatory cytokines including tumour necrosis 
factor (TNF)-α, interleukin (IL)-1 and interleukin (IL)-6 in the peripheral blood and 





demonstrated that the cytokines and pro-inflammatory cytokines can activate the 
HPA axis and impair the central serotonin system (Dantzer et al., 2008; Miller et al., 
2013). These cytokine-induced changes in neurotransmitter and neuroendocrine 
function have, in turn, been correlated with the development of MDD (Dantzer et al., 
2008; Anisman, 2009; Raison et al., 2009; Miller et al., 2013). Moreover, 
administration of cytokines including interferon (IFN)-α and cytokine inducers such 
as lipopolysaccharide (LPS) have been shown to lead to host behavioural changes 
that overlap with those seen in MDD patients (Reichenberg et al., 2001; Brydon et 
al., 2008). A number of cytokines and their signalling pathways have been shown to 
activate the enzyme indoleamine 2,3 dioxygenase (IDO), which in turn breaks down 
tryptophan, the precursor of serotonin into kynurenine (Schwarcz and Pellicciari, 
2002; Dantzer et al., 2008). The breakdown of  tryptophan is believed to contribute 
to reduced serotonin availability and cause depressive symptom (Neumeister et al., 
2004) 
 
1.1.4 Diagnostic criteria of MDD 
Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-
V) (American Psychiatric Association, 2013) is the current reference used by mental 
health professionals and psychiatrist to diagnose mental disorders. According to 
DSM-V, for a diagnosis of MDD at least five or more of the following symptoms 
must be present during the same 2-weeks period and it represents a change from 
previous functioning. At least one of the symptoms is either depressed mood or loss 





i. Depressed mood most of the day, nearly every day, as indicated by either 
subjective report (e.g. feels sad or empty) or observation made by others (e.g. 
appears tearful). Note: In children and adolescents, can be irritable mood.  
ii. Markedly diminished interest or pleasure in all, or almost all, activities most 
of the day, nearly every day (as indicated by either subjective account or 
observation made by others).  
iii. Significant weight loss when not dieting or weight gain (e.g. a change of 
more than 5 percent of body weight in a month), or decrease or increase in 
appetite nearly every day. Note: In children, consider failure to make 
expected weight gains.  
iv. Insomnia or hypersomnia nearly every day.  
v. Psychomotor agitation or retardation nearly every day (observable by others, 
not merely subjective feelings of restlessness or being slowed down).  
vi. Fatigue or loss of energy nearly every day.  
vii. Feelings of worthlessness or excessive or inappropriate guilt (which may be 
delusional) nearly every day (not merely self-reproach or guilt about being 
sick).  
viii. Diminished ability to think or concentrate, or indecisiveness, nearly every 
day (either by subjective account or as observed by others).  
ix. Recurrent thoughts of death (not just fear of dying), recurrent suicidal 
ideation without a specific plan, or a suicide attempt or a specific plan for 
committing suicide.  
The symptoms must be accompanied by significant distress or impairment in social, 





to the direct physiological effects of a substance (e.g. drug abuse, medication) or 
medical condition (e.g. hypothyroidism)(American Psychiatric Association, 2013).  
 
1.1.5 Assessment tools for MDD 
Various assessment tools have been developed by medical practitioner to 
measure the depressive symptoms in patients. The use of rating scales is a well-
established technique for assessing the severity of mental illness including MDD. In 
general, the rating scalecan be divided into two groups; patient-rated scale and 
clinician-rated scale. Total score obtained from the rating scales provides an 
indication of the severity of MDD for a time period (Cusin et al., 2009; Uher et al., 
2012). According to Uher et al. (2012), a complete assessment of depression should 
include both patient-rated scale and clinician-rated scale (Uher et al., 2012). 
 
The commonly used patient-rated scales for MDD were Beck Depression Inventory 
(BDI), Patient Health Questionnaire (PHQ), Depression, Anxiety and Stress Scale 
(DASS), and Hospital Anxiety Depression Scale (HADS) (Firdaus Mukhtar and Tian 
P.S. Oei, 2011a). In Western studies, BDI has been established as the most 
commonly used outcome measure either in clinical setting or in research practice 
(Stahl, 2000). Previous studies also support the notion that BDI can be used as an 
instrument with confidence to measure the levels of depressive symptoms in 
Malaysian (Firdaus Mukhtar and Tian P.S. Oei, 2011a). BDI had been proven to 
have good psychometric properties with acceptable internal consistency and 







Beck Depression Inventory (BDI) was developed by J. Erbaugh based on the records 
of statements made by individuals with depressive disorders during 
psychotherapeutic sessions (Beck et al., 1961). BDI has 21-items that assess all 
DSM-V diagnostic symptoms of depression and additional symptoms (e.g. 
irritability). A large proportion of BDI items focus on the cognitive symptoms of 
depression, such as guilt, self-esteem, feeling disappointed in oneself, feeling of 
being punished, and pessimism (Uher et al., 2008). Each item is composed of four 
first-person statements graded by the degree of depression severity it typically 
represents and rated on a 4 point ordinal scale (0 to 3). BDI was originally designed 
to be read out to the patient by an interviewer, but has commonly been used as self-
report questionnaire for literate patients. The total BDI score is calculated by 
summing the 21 items and the score can range from 0 to 63. Higher score reflects 
more severe depression. The advantages of BDI scale over clinician-rated scales are 
they may take less time, do not require trained personnel, and their administration 
and scoring process appear more standardized (Cusin et al., 2009). 
 
The commonly used clinician-rated scales in clinical studies were Hamilton 
Depression Rating Scale (HDRS), Montgomery-Asberg Depression Rating Scale 
(MADRS) and Quick Inventory of Depressive Symptomatology (QIDS) (Cusin et 
al., 2009; Uher et al., 2012). However, MADRS has been found to be internally 
consistent and discriminate levels of depression severity more accurately than other 
clinician-rating scales (Carmody et al., 2006; Bernstein et al., 2010). The inter-rater 






Montgomery–Åsberg Depression Rating Scale (MADRS) was develop in the late 
1970. MADRS consist of 10 item assessing symptoms of depression that were found 
to be responsive to treatment (Montgomery and Asberg, 1979). It is commonly used 
in clinical practice and clinical studies for weekly administration. MADRS focused 
more toward psychological, as opposed to somatic aspects of depression (Cusin et 
al., 2009). Sad mood is assessed by two item that capture the observer perspective, 
and reported subjective experience respectively. The other eight items assess tension, 
sleep, appetite, concentration, lassitude (activity), inability to feel (anhedonia), 
pessimism, and suicidal thoughts. Each item is rated on a 7 point (0 to 6) ordinal 
scale. A total score is computed as the sum of the 10 items and the score range from 
0 to 60. A higher total scores will reflect more severe depression (Müller et al., 
2003). MADRS can be used by both psychiatrists and professionals without a 
specific or with minimal psychiatric training (Cusin et al., 2009).  
 
1.1.6 Treatment of MDD 
Several treatment approaches to MDD are currently available. These 
approaches include pharmacotherapy, psychotherapy, electroconvulsive treatment 
(ECT) and transcranial magnetic stimulation (TMS). Antidepressants drugs were 
used to reduce the symptoms of depression and help depressed people feel the way 
they did before they became depressed. Antidepressant drugs commonly used for the 
treatment of MDD are selective serotonin reuptake inhibitors (SSRIs) (e.g. 
Citalopram, Escitalopram, Fluoxetine, Paroxetine, Sertraline), serotonin-
norepinephrine reuptake inhibitors (SNRIs) (e.g. Venlafaxine, Duloxetine), tricyclic 
antidepressants (e.g. Amitriptyline, Imipramine, Doxepin) and monoamine oxidase 





Halverson, 2016). Although choices of antidepressant drugs appear to be many, all 
current antidepressant drugs have essentially similar mechanism of action through 
the monoaminergic pathways (S. W. Tang et al., 2010). 
 
Besides pharmacological treatment, MDD patients also have the alternative choice of 
psychotherapy treatments. Several studies stated that a combination of 
pharmacotherapy and psychotherapy provides the quickest and most sustained 
response in MDD patients (Trivedi Madhukar, 2008; Karyotaki et al., 2016). 
Psychotherapies normally used for adult with MDD including interpersonal 
psychotherapy (IPT), cognitive-behavioural therapy (CBT), problem-solving therapy 
(PST), behavioural activation (BA) and contingency management therapy (Valdivia 
and Rossy, 2004; Halverson, 2016).  
 
Electroconvulsive treatment (ECT) and transcranial magnetic stimulation (TMS) be 
an option for those who have not responded to antidepressants. The treatments are 
known to impact the function of neurotransmitters in our brain and typically offers 
immediate relief of even severe depression (Halverson, 2016). The use of ECT and 
TMS are usually limited to MDD patients that are highly resistant to antidepressant 
treatment or have high risk of medical morbidity and mortality (Valdivia and Rossy, 
2004; National Institute of Mental Health, 2016a). However, the use of ECT can give 
several side effect to patients like headache, muscle pain, nausea, fatigue and 
temporary loss of memory. In serious cases, ECT may cause cardiovascular 






1.2 Human Immune System and Lymphocyte Subsets 
 
1.2.1 Cell of immune system 
Human immune system consists of complex network of cells, tissues and 
organs that work together to protect the body against foreign substances (antigen) 
such as bacteria, viruses, fungi and other parasites. The immune cells are known as 
white blood cells or leukocytes. Leukocytes can be divided into five different types 
based on their physical and functional characteristics. They are neutrophils, 
eosinophils, basophils, lymphocytes, and monocytes (Elgert, 2009). Lymphocytes are 
the smallest member of the leukocytes family that capable of complex biological 
response and activities. Lymphocytes are round cells with 6 to 15 µm in diameter 
and have a large nucleus and a coarse, dense cytoplasm. They represent 20-40% of 
the body’s leukocytes and are found circulating between blood and lymphoid tissues 
(Abbas et al., 2014).  
 
All lymphocyte develop from pleuripotent haematopoietic stem cells originate in the 
bone marrow through a process called haematopoiesis. Pleuripotent haematopoietic 
stem cells (HSCs) are capable of giving rise to multiple cell lineages including 
erythrocytes, platelets, myeloid progenitor cells and lymphoid progenitors cells. 
Myeloid progenitor cells give rise to neutrophils, basophils, and eosinophils. They 
also give rise to monocytes that can further differentiate to macrophages or dendritic 
cells (DCs), depending upon exposure to different cytokine millieus. While, 
lymphoid progenitors cells develop into lymphocytes in the microenvironment of the 
primary lymphoid organ (thymus or bone marrow). The newly formed lymphocytes 





lymphocyte subsets known as T lymphocyte, B lymphocytes or natural killer (NK) 
cells (Abbas et al., 2014). Although all lymphocytes are morphologically similar and 
rather remarkable in appearance, they are extremely heterogeneous in lineage, 
function, and phenotype (Elgert, 2009). 
 
T lymphocytes and B lymphocytes express specific receptors for antigen and thus the 
key mediators of adaptive immunity. In contrast, NK cells do not express specific 
receptor for antigen and they play a crucial role in innate immunity (Elgert, 2009). 
These cells are often distinguished by surface protein that may be identified by 
panels of monoclonal antibodies. The standard nomenclature for these proteins is the 
“CD” (cluster of differentiation) with numerical designation (e.g. CD3, CD4, CD8, 
CD25, etc.), which is used to delineate surface protein that define a particular cell 
type or stage of cell differentiation (Figure 1.1) (Abbas and Lichtman, 2009).  
 
Circulating lymphocytes play a key roles in maintaining immune homeostasis against 
invading pathogens and damaged host-derived cells that might otherwise destroy the 
immune balance. Many immune-related disorders such as autoimmune diseases, 
immunodeficiency syndromes, allergies, transplantation rejection, and leukemia are 
involved in alterations of lymphocyte subsets (Abul and Andrew, 2011). Recently, it 
has been reported that mental disorder like post-traumatic stress disorder, panic 
disorder and major depressive disorder were also associated with the alteration of 















1.2.2 Total T cells (CD3
+ 
T cells) 
Lymphocytes that mature in the thymus after having originated in the foetal 
liver and adult bone marrow are known as T lymphocytes or T cells. Majority of T 
cells are small lymphocytes, possessing a large nucleus with very few 
intracytoplasmic organelles. T cells play a central role in cell mediated immunity and 
are functionally and phenotypically heterogeneous. T cells express T cell receptors 
(TCR) on the cell surface which can recognize a specific antigen. T cells that express 
αβ TCRs are considered part of the adaptive immune response and those expressing 
γδ TCRs are considered part of the innate immune response. αβ T cells can be 
divided into several subsets depending upon the co-receptor expressed and each have 
a distinct function. The main subsets of αβ T cells are T helper cells (CD4
+
 T cells) 
and T cytotoxic cells (CD8
+
 T cells) (Abbas et al., 2014).  
 
In 1990s, a new subset of T cells were discovered known as regulatory T cells 
(Tregs). Tregs has been found to play a crucial role in immune regulation. T cell 
dysregulation is present in many diseases including autoimmune diseases, 
immunodeficiency diseases and also psychological stress-related diseases 
(Atanackovic et al., 2006; Yamanouchi et al., 2007; Kuhn et al., 2009; Hisamatsu et 
al., 2016). Through their neuroprotective and anti-inflammatory effects, T cells may 







1.2.3 T helper cells (CD4
+
 T cells) 
T helper (TH) cells are a subset of T lymphocytes that express the surface 
protein CD4 and are also referred as CD4
+
 T cells. The main function of CD4
+
 T 
cells is to secrete cytokines for the activity of other immune cells (Zhu et al., 2009). 
CD4
+
 T cells generally provide positive signals to other subsets, for example, they 
cooperate with B cells in the production of antibodies and in the maturation of T 
cytotoxic cells (Crotty, 2015). In addition, these cells also release cytokines that help 
macrophages to kill micro-organisms (Zhu and Paul, 2008). 
 
T helper cells can be divided into three broad subsets, TH1, TH2, and TH17. The 
distinction between the subsets is essentially phenotypic and is based on the profile 
of the cytokines they expressed (Zhu et al., 2009). TH1 cells synthesize IL-2, IFN-γ, 
TNF-α and TNF-β (lymphotoxin). These cytokine activate CD8
+
 T cells and NK 
cells. Once these cells have been activated, they kill host cells that have been 
infected with viruses or intracellular bacteria (Zhu et al., 2009). 
 
TH2 cells synthesize IL-4, IL-5, and IL-13. IL-4 and IL-13 influence B cells class 
switch to IgE and IgG in humans, while IL-5 activates eosinophils. TH17 cells 
synthesize and secrete the IL-17 family of cytokines (particularly IL-17A anf IL-
17F) and IL-22. These cytokine promote the inflammatory response at the mucosal 
sites. It has been found that, TH17 cells and cytokines are involved in many 
autoimmune diseases including rheumatoid arthritis, multiple sclerosis and 
inflammatory bowel disease (Bettelli et al., 2008; Hisamatsu et al., 2016). Loss of 
functional CD4
+
 T cells leads to the symptomatic stage of infection known as the 





1.2.4 T cytotoxic cells (CD8
+ 
T cells) 
T cytotoxic (TC) cells are a subset of T lymphocytes that express the surface 
protein CD8 and referred as CD8
+
 T cellsor cytotoxic T lymphocyte (CTL). CD8
+ 
T 
cell express a dimeric co-receptor CD8, usually composed of one CD8α and one 
CD8β chain. CD8
+
 T cells are very important for immune defence against 
intracellular pathogens, including viruses and bacteria, and for tumour surveillance 
(Abbas and Lichtman, 2009). When a CD8
+
 T cell recognises its antigen and 
becomes activated, it has three major mechanisms to kill infected or malignant cells. 
The first is secretion of cytokines, primarily tumornecrosis factor (TNF)-α and 
interferon (IFN)-γ, which have anti-tumour and anti-viral microbial effects (Price et 
al., 1999). 
 
The second mechanism is the production and release of cytotoxic granules. These 
granules, also found in  NK cells, contain two families of proteins; perforin and 
granzymes. Perforin forms a pore in the membrane of the target cell. This pore 
allows the granzymes to enter the infected or malignant cell. Granzymes are serine 
proteases which cleave the proteins inside the cell, shutting down the production of 
viral proteins and ultimately resulting in apoptosis of the target cell. CD8
+
 T cells can 
contribute to protection against subsequent encounters with the same antigen 
(Stenger et al., 1998). 
 
The third mechanism is the destruction of infected cells via Fas/Fas ligand  
interactions. The cell-surface Fas receptor (Fas) is a member of the tumour necrosis 
factor (TNF) and nerve growth factor (NGF) family of receptors (Schulze‐Osthoff et 
al., 1998). Activated CD8
+





which binds to its receptor, Fas, on the surface of the target cell. This binding causes 
Fas molecules on the surface of the target cell to trimerise, which pulls together the 
signalling molecules. These signalling molecules result in the activation of the 
caspase cascade, which cause the apoptosis of the target cell (Hanabuchi et al., 1994; 
Waring and Müllbacher, 1999). Since CD8
+
 T cells can express both molecules, 
Fas/FasL interactions are a mechanism by which CD8
+
 T cells can kill each other, to 
eliminate immune effector cells during the contraction phase at the end of an immune 
response (Hanabuchi et al., 1994). 
 
However, in addition to their critical role in immune defense against viruses, and 
tumors, CD8
+
 T cells can also contribute to an excessive immune response that leads 
to immunopathology, or immune-mediated damage. For example, self-antigens 
released from CD8
+ 
Tcell lysis during the process of killing virus-infected cells can 




T cells, causing them 
autoreactive. Eventually, this might lead to damage at the site of inflammation or 

















Natural killer (NK) cells are large granular lymphocytes comprising ≈15% of 
peripheral blood lymphocytes (Robertson and Ritz, 1990). NK cells develop from 
CD34
+
 hematopoietic progenitor cells (HPCs) within the microenvironment of the 
bone marrow. They are characterized phenotypically by the expression of CD16 and 
CD56 (Trinchieri, 1989). NK cells are the crucial component of innate immune 
system which display natural cytotoxic activity (Robertson and Ritz, 1990). They 
lack both immune memory and major histocompatibility complex (MHC) restriction, 
and are activated by the secretion of interleukin-2 (IL-2) and interferon-γ (IFN-γ) 
(Trinchieri, 1989).  
 
NK cells express a functional heterodimeric interleukin-2 receptor (IL-2Rβγ), with 
intermediate affinity for IL-2 (Caligiuri et al., 1990). NK cells also express 
constitutively several receptors for monocyte-derived cytokines (monokines), 
including IL-1, IL-10, IL-12, IL-15 and IL-18 (Carson et al., 1995; Kunikata et al., 
1998; Fehniger et al., 1999). Besides that, several other studies have identified 
human NK cells also expressed other surface molecule like CD43 (Aguado et al., 
1999), CD55 and CD59 (Solomon et al., 1995), CD57 and HLA-DR (Sedlmayr et 
al., 1996).  
 
NK cells play a major function in the elimination of compromised host cells, such as 
tumor or virus-infected cells. NK cell mediated killing involves exocytosis of 
cytoplasmic granules containing perforin and granzyme through a metabolically 
active process (Winkler et al., 1996). They also have the ability to kill target cells via 





(TRAIL) and Fas ligand (FasL) (Screpanti et al., 2001; Takeda et al., 2005). In 
addition, NK cells have the capacity to produce an early source of immunoregulatory 
cytokines. During the innate immune response to infection, monokines stimulate NK 
cells to produce immunoregulatory cytokines like IFN-γ, TNF-β and granulocyte 
macrophage-colony stimulating factor (GM-CSF) that are important to the early host 
defense against a variety of viral, bacterial, and parasitic pathogens (Scharton-
Kersten and Sher, 1997; Biron et al., 1999).  
 
NK cells also act as regulatory cells to influence various other cell types, such as 
dendritic cells (DCs), T cells, B cells and endothelial cells. For example, NK cells 
can kill immature DCs in humans and thereby influencing DC homeostasis. In 
addition, by means of IFN-γ and TNF, NK cells can promote the maturation of DCs 
which in turn activate the NK cells by means of IL-12 (Walzer et al., 2005). IL-2 can 
promotes NK cell proliferation, cytotoxicity and cytokine secretion. In the inflamed 
lymph node, NK cells can promote the priming TH1 cells by secreting IFN-γ (Martín-
Fontecha et al., 2004; Morandi et al., 2006). Futhermore, NK cells can also kill 
activated T cells and suppress autoreactive B lymphocytesin vitro (Takeda and 
Dennert, 1993). 
 
NK cells are unique as they have the ability to recognize stressed cells in the absence 
of antibodies and major histocompatibility complex (MHC), which allowing for a 
much faster immune reaction (Robertson and Ritz, 1990; Cooper et al., 2001). This 
role is important because harmful cells that are missing MHC class I markers cannot 
be detected and destroyed by other immune cells. In addition to their major functions 





Numerous studies have demonstrated their ability to readily adjust to the immediate 
environment and formulate antigen-specific immunological memory which are 
fundamental for responding to secondary infections with the same antigen (Pyzik and 
Vidal, 2009; Rölle et al., 2013). 
 
1.2.6 B cells (CD19
+
 B cells) 
B cells also known as B lymphocytes are the effectors of humoral immunity.  
B cells are the only immunoglobulin (Ig) producing cells. They constitute 
approximately 15% of peripheral blood leukocytes and are found in the bone 
marrow, blood, lymphoid organs and lymph. B cells mature in the bone marrow (in 
mammals) or Bursa of Fabricus (in birds) (Cooper and Alder, 2006). Unlike T cells 
and NK cells, B cells express B cell receptor (BCRs) on their membrane. BCRs 
allow the B cell to bind a specific antigen, against which it will initiate an antibody 
response. Mature B cells differentiate into either plasma B cells or memory B cells 
(Elgert, 2009). During their development stages, B cells expressed several surface 
molecule such as CD19, CD20, CD21, CD22, CD23, CD24, CD40, CD72 and 
CD81. However, among all the surface molecule, only CD19 is expressed in all 
stages of B cell development including the mature B cell (but not the plasma cell) 
(LeBien and Tedder, 2008). So the expression of CD19 is a useful marker of all cells 
in the B-cell lineage up to the plasma cells. Besides that, B cells also express MHC 
class I and II molecules. The expression of MHC class II molecules allows them to 
present antigen to T helper cells (LeBien and Tedder, 2008). 
 
The main function of B cells is antibody production. The antibodies are secreted by 





them and making them easier targets for phagocytes and activation of the 
complement system. In addition to their essential role in humoral immunity, B cells 
also mediate or regulate many other functions essential for immune homeostasis. Of 
major importance, B cells are required for the initiation of T cell immune responses. 
The antigen-specific interactions between B and T cells may require the antigen to be 
first internalized by the BCR, processed, and then presented in an MHC-restricted 
manner toT cells (LeBien and Tedder, 2008). Previous studies also demonstrated that 
B cells are essential for optimal CD4 T cell activation during immune responses to 
low-dose foreign antigens and autoantigens (Bouaziz et al., 2007).  
 
While critical for normal immune system development, B cells are also important for 
its maintenance. B cells can release immunomodulatory cytokines that can influence 
a variety of T cell, APC, and dendritic cells functions, regulate lymphoid tissue 
organization and neogenesis, regulate wound healing and transplanted tissue 
rejection, and influence tumor development. B cells can also function as cytokine-
producing effector cells that influenceT-cell differentiation (Harris et al., 2000). One 
phenotypically distinct subset, designated as B10 cells has been shown to uniquely 
regulate T cell mediated inflammatory responses through the production of IL-10 









1.2.7 Regulatory T cells (Tregs) 
 
1.2.7 (a)  Discovery of Tregs 
Tregs is a newly discovered lymphocyte subsets compared to T helper, T 
cytotoxic, NK cells and B cells. In the early 1970s, Gershon and Kondon proposed 
that a specialized populations of T cells supressed the immune responses of other 
lymphocytes (Gershon and Kondo, 1970). The suppressor T cells, which were 
characterized by expression of the CD8 cell surface marker, have been intensively 
studied over the following years in various fields of immunology.  However, because 
of the poor characterization of the cells and the lack of specific markers, the concept 
of suppressor T cells was largely abandoned by the end of the 1980s (Sakaguchi et 
al., 2007).  
 
In mid-1990s, renewed interest in suppressor T cells emerged with the identification 
of CD4
+
 T cells population which have the ability to downregulate T cell function. 
The suppressor T cells was named as regulatory T cells (Tregs). Tregs was observed 





However, further studies shows that CD25 is not unique to Tregs only, as it was also 
expressed on activated effector CD4
+
 T cells. This has made it difficult to isolate a 
pure Tregs subsets for functional studies (Sakaguchi et al., 2007).  
 
Studies on the Scurfy disease in mice and immune dysregulation polyendocrinopathy 
enteropathy X-linked syndrome (IPEX) in humans led to the identification of a 
marker specific for Tregs, known as Foxp3 (forkhead box P3). Foxp3 is a 





shown to induce non-regulatory T cells to acquire suppressive activity in the 
periphery (Hori et al., 2003). Therefore, Foxp3
+
 transcription factors is considered as 
the most reliable intracellular marker for functional Tregs to date and the Treg cells 






 Treg cells. 
 
1.2.7 (b) Characteristics of Tregs 
Natural Tregs represent approximately 5-10% of the total CD4
+ 
T cell 
population. In mice, CD4
+





 cells are Tregs. In human, the Treg are a heterogeneous population, in which 
not all CD25
+
 cells are Tregs. Studies by groups of scientists at Havard and the 
Royal Free and University College Medical School in London revealed that only 
those CD4
+ 
T cells that expressed very high level of CD25
+
, representing 
approximately 2-3% of total CD4
+
 T cells were Treg (Baecher-Allan et al., 2005).  
 
There are a number of Tregs subtypes with the best understood being those that 




 Treg cells development and function (Thompson and Powrie, 2004). Foxp3
+ 
Treg cells use the αβTCR for antigen recognition, and have a broad repertoire, 
comparable in size to, but largely distinct in composition from conventional CD4
+
 T 
cells (Pacholczyk et al., 2006; Wong et al., 2007). It have been found that, when 
Tregs lose this transcription factor they become ‘ex-Tregs’ which are effector-like T 
cells that no longer serve to regulate immune function (Zhou et al., 2009). Loss of 
function  or mutations in the human Foxp3 gene lead to IPEX syndrome, a severe 
multi-organ autoimmune and inflammatory disorder (Rudensky, 2011). 
 
